Clarity Pharmaceuticals Ltd
CU6 · ASX · Australia
Price data from its CU6 listing on CXA
claritypharmaceuticals.comFinancials as of FY2025–FY2026
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $7.24M, lower than 95% of all stocks globally
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
The statements on file don't all cover the same year: income statement FY2026, balance sheet FY2025, cash-flow statement FY2025. Each figure below is labelled with the year it comes from.
Financials view
Market Capitalization
583.87MAUD401.82M · vs all stocks (USD)
Revenue (TTM)
10.53MAUD7.24M · vs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.18xvs all stocks
52-Week Change
-65.25%vs all stocks
Forward Annual Dividend Yield
0.00%vs all stocks
Market Capitalization
583.87MAUD401.82M · vs all stocks (USD)
Enterprise Value
399.85MAUD275.18M · vs all stocks (USD)
Forward P/E
-5.82xvs Biotechnology peers
Price to Sales (TTM)
54.94xvs Biotechnology peers
Price to Book (MRQ)
3.11xvs Biotechnology peers
Enterprise to Revenue
37.99xvs Biotechnology peers
Enterprise to EBITDA
-3.70xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-1095.64%vs Biotechnology peers
Return on Assets (TTM)
-45.12%vs Biotechnology peers
Return on Equity (TTM)
-77.55%vs Biotechnology peers
Revenue (TTM)
10.53MAUD7.24M · vs all stocks (USD)
Revenue per Share (TTM)
0.0290AUDUpdated Oct 29, 2026Quarterly Revenue Growth
-1.10%vs Biotechnology peers
Gross Profit (TTM)
10.53MAUD7.24M · vs all stocks (USD)
EBITDA (TTM)
-108.10MAUD-74.39M · vs all stocks (USD)
Net Income (TTM)
-107.14MAUD-73.74M · vs all stocks (USD)
Operating Cash Flow (TTM)
-92.55MAUD-63.69M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-59.44MAUD-40.90M · vs all stocks (USD)
Forward Annual Dividend Yield
0.00%vs all stocks
Trailing Annual Dividend Rate
0.00AUDUpdated Oct 29, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
EPS (Basic)
-0.2911AUDFY2026 · Jun 30, 2026EPS (Diluted)
-0.2911AUDFY2026 · Jun 30, 2026Basic Shares Outstanding
368.03MSharesFY2026 · Jun 30, 2026Diluted Shares Outstanding
368.03MSharesFY2026 · Jun 30, 2026Cash & Cash Equivalents (End of Period)
47.68MAUDFY2025 · Jun 30, 2025Income Tax Paid
719.25KAUDFY2025 · Jun 30, 2025Capital Expenditures
-182.74KAUDFY2025 · Jun 30, 2025Sale of Investments
52.17MAUDFY2025 · Jun 30, 2025Net Investing Cash Flow
51.99MAUDFY2025 · Jun 30, 2025Common Stock Repurchase
-193.39KAUDFY2025 · Jun 30, 2025Net Financing Cash Flow
2.21MAUDFY2025 · Jun 30, 2025Shares Outstanding
321.47MSharesUpdated Oct 29, 2026Float Shares
288.69MSharesUpdated Oct 29, 2026% Held by Insiders
21.15%vs all stocks
% Held by Institutions
25.98%vs all stocks
Total Cash (MRQ)
178.25MAUD122.67M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.4780AUDUpdated Oct 29, 2026Total Debt (MRQ)
0.00AUDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
16.09xvs Biotechnology peers
Book Value per Share (MRQ)
0.4990AUDUpdated Oct 29, 2026Total Assets
101.17MAUD69.63M · vs all stocks (USD)
Total Current Assets
100.61MAUDFY2025 · Jun 30, 2025Total Liabilities
10.94MAUDFY2025 · Jun 30, 2025Total Non-current Assets
566.00KAUDFY2025 · Jun 30, 2025Total Non-current Liabilities
561.75KAUDFY2025 · Jun 30, 2025Total Current Liabilities
10.38MAUDFY2025 · Jun 30, 2025Cash
18.28MAUDFY2025 · Jun 30, 2025Cash Equivalents
29.41MAUDFY2025 · Jun 30, 2025Cash & Cash Equivalents
47.68MAUDFY2025 · Jun 30, 2025Other Short-term Investments
36.43MAUDFY2025 · Jun 30, 2025Accounts Payable
3.21MAUDFY2025 · Jun 30, 2025Common Stock (Book)
255.89MAUDFY2025 · Jun 30, 2025Retained Earnings
-176.99MAUDFY2025 · Jun 30, 2025Total Shareholders' Equity
90.23MAUD62.10M · vs all stocks (USD)
52-Week Low
1.51AUDUpdated Oct 29, 202652-Week High
5.14AUDUpdated Oct 29, 202652-Week Change
-65.25%vs all stocks
Beta
1.18xvs all stocks
50-Day MA
2.10AUDUpdated Oct 29, 2026200-Day MA
2.66AUDUpdated Oct 29, 2026Avg 10-Day Volume
3.00MSharesUpdated Oct 29, 2026Avg 30-Day Volume
2.40MSharesUpdated Oct 29, 2026Diluted EPS (TTM)
-0.2800AUDUpdated Oct 29, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 245
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $7.24M, lower than 95% of all stocks globallySignificant
Revenue (USD): 7,244,223.747Global P5: 37,231,057.061
Companies that share the same coordination system — how they create, deliver, or capture value.
Tibet Aim Pharm Inc.
Tier 1ProductionApproval-Gated PipelineRule
Assembly Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shoulder Innovations, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Altimmune, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shaanxi Panlong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tectonic Therapeutic Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Rezolute, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Yantai Zhenghai Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Universal Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Kamada Ltd.
Tier 1ProductionApproval-Gated PipelineRule